Results 31 to 40 of about 1,973 (178)

Evaluation of the In Vitro Efficacy of Sevelamer Hydrochloride and Sevelamer Carbonate [PDF]

Journal of Pharmaceutical Sciences, 2016
The objective of this project is to develop an in vitro approach that can be used to determine the phosphate binding capacity of sevelamer hydrochloride and carbonate for both drug products and active pharmaceutical ingredients (APIs). A simple and efficient inductively coupled plasma spectrometer method for analysis of phosphate at physiologically ...
Yongsheng, Yang, Adil, Mohammad, Robert T, Berendt, Alan, Carlin, Mansoor A, Khan, Patrick J, Faustino   +5 more
openaire   +2 more sources

The Influence of Sevelamer Hydrochloride and Calcium Carbonate on Markers of Inflammation and Oxidative Stress in Hemodialysis at Six Months of Follow-Up

Frontiers in Medicine, 2021
Patients with end-stage renal disease (ESRD) present alterations in mineral and bone metabolism. Hyperphosphatemia in ESRD is considered an independent risk factor for cardiovascular disease (CVD), increasing morbidity, and mortality.
Elodia Nataly Díaz-De la Cruz, José Ignacio Cerrillos-Gutiérrez, Andrés García-Sánchez, Carlos Gerardo Prado-Nevárez, Jorge Andrade-Sierra, Basilio Jalomo-Martínez, Adriana Banda-López, Enrique Rojas-Campos, Alejandra Guillermina Miranda-Díaz   +8 more
doaj   +1 more source

Repurposing of sevelamer as a novel antidote against aluminum phosphide poisoning: An in vivo evaluation

Heliyon, 2023
Aluminum phosphide (AlP) is widely used for protecting grains from pests. AlP releases toxic phosphine gas (PH3) while exposed to humidity. Poisoning with these tablets is dangerous and can cause death or serious injuries. Up to now, no definite antidote
Reza Heidari, Hamid Reza Mohammadi, Fazel Goudarzi, Fatemeh Farjadian   +3 more
doaj   +1 more source

Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients. [PDF]

Nephrol Dial Transplant, 2019
Background Treatment of hyperphosphataemia is the primary goal of chronic kidney disease–mineral and bone disorder (CKD-MBD) management.
Ketteler M, Sprague SM, Covic AC, Rastogi A, Spinowitz B, Rakov V, Walpen S, Floege J.   +7 more
europepmc   +2 more sources

Lower gastrointestinal bleeding in a patient receiving sevelamer: Case report

SAGE Open Medical Case Reports, 2021
Phosphate binders such as sevelamer are widely used in patients with chronic kidney disease to lower serum phosphate levels. We present a case of a 67-year-old woman with lower gastrointestinal bleeding after 9 days of using sevelamer carbonate (Renvela ®
Tessa S Schoot, Tessa EH Römkens, Ellen K Hoogeveen   +2 more
doaj   +1 more source

Short-term effects of sevelamer-carbonate on fibroblast growth factor 23 and pulse wave velocity in patients with normophosphataemic chronic kidney disease Stage 3. [PDF]

Clin Kidney J, 2019
Background: High concentrations of both phosphate and fibroblast growth factor 23 (FGF23) observed in chronic kidney disease (CKD) are associated with an increased risk of cardiovascular morbidity and mortality.
Bouma-de Krijger A, van Ittersum FJ, Hoekstra T, Ter Wee PM, Vervloet MG.   +4 more
europepmc   +2 more sources

Supplementary Material for: Efficacy and Safety of Sevelamer Carbonate in Chinese Nondialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized, Double-Blind, Parallel-Group Study

, 2022
Introduction: Previous studies suggested that sevelamer carbonate is well tolerated with a favorable efficacy and safety profile in both dialysis and nondialysis patients in Europe; however, the efficacy remains controversial, and few studies have ...
Wang L.-H. (14264411), Dai C. (4161532), Wei J.-L. (14264408), Liu H. (3215136), Chen M.-H. (10324376), Lu W.-H. (14264414), Li S.-M. (4161058), Liu H.-F. (14264393), Tang D.-X. (14264423), Zhao M.-H. (8746173), Wan J.-X. (14264402), Yang Y.-Q. (11803097), Yu X.-Q. (14264426), Chen W. (2828783), Yang J.-W. (14264417), Shi H.-B. (14264405), Long G. (14184281), Tang Y. (4111276), Zhao H.-W. (4665511), Cao L.-Y. (14264420), Chen X.-N. (14264399), Chen Q.-K. (14264396)   +21 more
core   +1 more source

Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients

Renal Failure, 2023
This study was designed to examine the relative safety and efficacy of sevelamer in the treatment of chronic kidney disease (CKD) patients in comparison to placebo, calcium carbonate (CC), or lanthanum carbonate (LC). The PubMed, Embase, Cochrane Library,
Qian Zeng, Yuanlong Zhong, Xiqiu Yu
doaj   +1 more source

A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis

Saudi Journal of Kidney Diseases and Transplantation, 2014
In the present study, a comparative evaluation of the effects of calcium acetate, calcium carbonate, sevelamer hydrochloride and lanthanum carbonate was carried out in 120 patients with end stage kidney disease (ESKD) undergoing hemodialysis. Biochemical
Viken A Prajapati, Varsha J Galani, Pankaj R Shah   +2 more
doaj   +1 more source

Use of phosphate binders in end-stage renal disease: An experience from a secondary care hospital in United Arab Emirates

Journal of Pharmacy and Bioallied Sciences, 2019
Objective: Hyperphosphatemia in end-stage renal disease (ESRD) is associated with many serious patient-level consequences including cardiovascular events and mortality.
Syed Arman Rabbani, Sathvik B Sridhar, Padma G M Rao, Martin T Kurian, Basset E Essawy   +4 more
doaj   +1 more source